Gilead Sciences, Inc. (GILD) on Thursday announced positive topline results from its Phase 3 ARTISTRY-1 trial evaluating the company's single-tablet regimen of bictegravir and lenacapavir (BIC/LEN) for the treatment of HIV.
Phase 2/3 ARTISTRY-1 study compared the combination of bictegravir and lenacapavir against current multi-tablet therapies in people with HIV who are virologically suppressed on complex regimens.
The trial met its primary endpoint, demonstrating that BIC/LEN was statistically non-inferior in efficacy to multi-tablet regimens. The regimen was generally well tolerated, with no new or significant safety concerns observed.
Gilead said it plans to file the Phase 3 data from the ARTISTRY trials with regulatory authorities.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.